Killen Group’s Myriad Genetics MYGN Stock Holding History

Killen Group’s Portfolio MYGN Stock Details MYGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q1	$5.49M	Sell	146,611 -219,694	-60%	-$8.28M	0.63%	55
2015 Q4	$15.8M	Sell	366,305 -15,460	-4%	-$653K	1.63%	17
2015 Q3	$14.3M	Sell	381,765 -50,600	-12%	-$1.8M	1.34%	22
2015 Q2	$14.7M	Sell	432,365 -20,675	-5%	-$703K	1.11%	34
2015 Q1	$16M	Sell	453,040 -150,265	-25%	-$5.38M	1.15%	36
2014 Q4	$20.5M	Sell	603,305 -26,785	-4%	-$950K	1.34%	26
2014 Q3	$24.3M	Sell	630,090 -15,075	-2%	-$562K	1.35%	23
2014 Q2	$25.1M	Sell	645,165 -71,335	-10%	-$2.65M	1.31%	22
2014 Q1	$24.5M	Sell	716,500 -33,590	-4%	-$1.04M	1.34%	17
2013 Q4	$15.7M	Buy	+750,090	New	+$19M	0.9%	57

Other funds holding MYGN

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

SCM

Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

IAM

Iridian Asset Management Westport, Connecticut $247M AUM 20.65% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

RIM

RS Investment Management San Francisco, California $9.73B AUM 3.24% 1-Year Est. Return

FCM

Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return

Killen Group's MYGN Position: Q1 2016 in Review

Killen Group reduced its Myriad Genetics (MYGN) stake by 60% in Q1 2016, selling an estimated $8.28M and leaving 146,611 shares worth $5.49M. The position accounts for 0.63% of the portfolio, ranked #55.

Killen Group first reported a position in MYGN in Q4 2013 and has held it in 10 quarters since. The position peaked at $25.1M in Q2 2014. 233 funds tracked by Wall St. Rank hold MYGN as of Q1 2016.

Killen Group held 146,611 shares of Myriad Genetics worth $5.49M as of Q1 2016.
Killen Group sold 219,694 Myriad Genetics shares in Q1 2016, an estimated $8.28M.
Myriad Genetics made up 0.63% of Killen Group's portfolio in Q1 2016, its #55 holding.
Killen Group first reported a position in Myriad Genetics in Q4 2013 and has held it in 10 quarters since.
Killen Group's Myriad Genetics position peaked at $25.1M in Q2 2014.
233 funds tracked by Wall St. Rank held Myriad Genetics as of Q1 2016.

Based on Killen Group's 13F filing for Q1 2016, filed 27 Apr 2016.